2,5-Dimethoxy-4-butylamphetamine

2,5-Dimethoxy-4-butylamphetamine
Names
Preferred IUPAC name
1-(4-Butyl-2,5-dimethoxyphenyl)propan-2-amine
Other names
2,5-Dimethoxy-4-butyl-amphetamine
2,5-Dimethoxy-4-butyl-1-ethyl-(alpha-methyl)amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C15H25NO2/c1-5-6-7-12-9-15(18-4)13(8-11(2)16)10-14(12)17-3/h9-11H,5-8,16H2,1-4H3 checkY
    Key: NGVDYAULSQKEGW-UHFFFAOYSA-N checkY
  • InChI=1/C15H25NO2/c1-5-6-7-12-9-15(18-4)13(8-11(2)16)10-14(12)17-3/h9-11H,5-8,16H2,1-4H3
    Key: NGVDYAULSQKEGW-UHFFFAOYAF
  • C1(=CC(=C(C=C1CC(C)N)OC)CCCC)OC
  • O(c1cc(c(OC)cc1CC(N)C)CCCC)C
Properties
C15H25NO2
Molar mass 251.37 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

2,5-Dimethoxy-4-butylamphetamine (DOBU) is a lesser-known psychedelic drug and a substituted amphetamine. DOBU was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), only low dosages of 2–3 mg were tested, with the duration simply listed as "very long". DOBU produces paresthesia and difficulty sleeping, but with few other effects. Compared to shorter chain homologues such as DOM, DOET and DOPR which are all potent hallucinogens, DOBU has an even stronger 5-HT2 binding affinity but fails to substitute for hallucinogens in animals or produce hallucinogenic effects in humans, suggesting it has low efficacy and is thus an antagonist or weak partial agonist at the 5-HT2A receptor.[1]

  1. ^ Seggel MR, Yousif MY, Lyon RA, Titeler M, Roth BL, Suba EA, Glennon RA (March 1990). "A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors". Journal of Medicinal Chemistry. 33 (3): 1032–6. doi:10.1021/jm00165a023. PMID 2308135.